Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Healthcare Shares
Mesoblast share price zooms 20% higher on coronavirus development
Share Market News
Is now the time to buy ASX biotech shares?
Share Fallers
Why Corporate Travel, Jumbo, Mesoblast, & Westgold shares are dropping lower
Share Market News
Why the Mesoblast share price is rising higher today
Share Fallers
Mesoblast share price lower despite Ryoncil FDA update
Healthcare Shares
2 ASX biotech shares that could be the next CSL
Share Market News
Why this ASX healthcare share hit a 52-week high on Monday
Share Gainers
Why Cann Group, Fortescue, Mesoblast, & Silver Lake shares are storming higher
Share Gainers
Why the Mesoblast share price is charging higher today
Share Gainers
Why the Mesoblast share price is charging higher today
Share Market News
Why the Paradigm share price is up 250% in 2019
Share Market News
ALL ORDINARIES finishes higher Tuesday: 8 ASX shares you missed
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
